Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium by Hussein, AA et al.
1 
 
Early Oncologic Failure after Robot-assisted Radical Cystectomy: Results from the 
International Robotic Cystectomy Consortium 
Ahmed A. Hussein
1,2
,
 
Matthias Saar
3
, Paul R. May
2
,
 
Youssef  E. Ahmed
2
, Carl J Wijburg
4 
, Lee 
Richstone
5
, Andrew Wagner
6
, Timothy Wilson
7
, Bertram Yuh
7
, Joan Palou Redorta
8
, Prokar 
Dasgupta
9
, Omar Kawa
9
, Mohammad Shamim Khan
9
, Mani Menon
10
, James O. Peabody
10
, 
Abolfazl Hosseini
11
, Franco Gaboardi
12 
, Ketan Badani
13
,Giovannalberto Pini
12
, Alexandre 
Mottrie
14
, Koon-ho Rha
15
, Ashok Hemal
16
, Michael Stockle
3
, John Kelly17, Wei Shen Tan 17 , 
Thomas J. Maatman
18
, Michael Woods19, Vassilis Poulakis20, Abdullah Erdem Canda21, Mevlana 
Derya Balbay
21
, Peter Wiklund
11
, Khurshid A. Guru
1
 
1
Roswell Park Cancer Institute, Buffalo, NY,
 2
Cairo University, Egypt, 
 3
University of the Saarland, 
Homburg Saar, Germany, 
4
 Rijnstate Hospital, Arnhem, the Netherlands, 
5
The Arthur Smith Institute for 
Urology, New York, NY, 
6
Beth Israel Deaconess Medical Center, Boston, MA, 
7
City of Hope and 
Beckman Research Institute, Duarte, CA, 
8
Fundacio Puigvert, Barcelona, Spain, 
9
Guy's Hospital and King's 
College London School of Medicine, London, UK, 
10
Henry Ford Health System, Detroit, MI, 
11
Karolinska 
University Hospital, Stockholm, Sweden, 
12
Luigi Sacco University Hospital, Milan, Italy, 
13
Columbia 
University Medical center, New York, NY,
 14
Onze-Lieve-Vrouw Ziekenhuis, Aalast, Belgium, , 
15
Yonsei 
University Health System Severance Hospital, Seoul, Korea, 
16
Wake Forest University Baptist Medical 
Center, Winston-Salem, NC, 
17
Division of Surgery and Interventional Science, University College London, 
Department of Urology, 
18
Michigan Urological Clinic, Grand Rapids, MI., 
19
Loyola University Medical 
Center, Illinois, 
20
Doctor's Hospital of Athens, Athens, Greece, 
21
Yildirim Beyazit University, School of 
Medicine, Ankara Ataturk Training and Research Hospital, Ankara, Turkey,  
 
 
 
2 
 
Corresponding Author: 
 Khurshid A. Guru, MD 
 Elm & Carlton St Buffalo, NY 14263  
Tel: 716-845-4155;  
Fax:716-845-3300   
Khurshid.guru@roswellpark.org 
Professor of Oncology 
Department of Urology, Roswell Park Cancer Institute 
A.T.L.A.S (Applied Technology Laboratory for Advanced Surgery) Program 
Keywords: Robot-assisted, cystectomy, recurrence, relapse, early, port-site, peritoneal 
carcinomatosis 
Acknowledgements: Vattikuti Foundation Collective Quality Initiative and Roswell Park 
Cancer Institute Alliance Foundation 
 
 
 
 
 
 
 
3 
 
Abstract 
Background: There have been concerns regarding incidences of peritoneal recurrences and 
adherence to key oncologic tenets during minimally invasive approaches to radical cystectomy  
Objective: To investigate the prevalence and variables associated with Early Oncologic Failure 
(EOF). 
Design, setting and participants: Retrospective review of the IRCC database (I-97906) which 
comprises 2648 patients was conducted. The final cohort included in this study comprised 1894 
patients from 23 institutions across 11 countries treated with RARC since 2003 
Intervention: EOF was defined as any disease relapse within 3 months of RARC. All 
institutions were surveyed for the pneumoperitoneum pressure used, breach of any oncological 
principle during RARC, the technique of specimen and lymph node removal, and whether urine 
spillage occurred.  
Outcome Measurements and Statistical Analysis: Univariate and multivariate (stepwise 
variable selection) logistic regression models were fit to evaluate preoperative, operative, and 
postoperative predictors of EOF following RARC. The Kaplan Meier method was used to depict 
overall survival for patients with EOF and Cox proportional hazards regression analysis to 
evaluate predictors of disease-specific and overall survival.  
Results and limitations: 305 patients (22%) experienced disease relapse, 220 (16%) developed 
distant, 154 (11%) local recurrence, 17 (1%) peritoneal carcinomatosis and 5 (0.4%) port-site 
recurrences. Seventy-one patients (5%) from 10 institutions developed EOF, and the incidence of 
EOF decreased from 10% in 2006 to 6% in 2015.  EOF patients experienced more pelvic 
recurrences (37% versus 22%, p=0.02), extrapelvic lymph node metastasis (23% versus 12%, 
p=0.03), and bone metastasis (24% versus 12%, p=0.03). On multivariate analysis, presence of 
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any complication (OR 2.87; 95% CI 1.38-5.96; p=0.004), extravesical disease (OR 3.73, 95% CI 
2.00-6.97, p<0.001), and nodal involvement (OR 2.14, 95% CI 1.21-3.80, p=0.008) were 
significant predictors of EOF. Patients with EOF demonstrated worse DSS and OS (23% and 
13%) at 1 and 3 years when compared to patients who experienced later or no recurrences (log 
rank p<0.001)  
Conclusion: The incidence of EOF following RARC is low and has decreased with time. 
Disease-related rather than technical or laparoscopy-related factors play a major role in 
occurrence of EOF after RARC. 
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Introduction 
Radical cystectomy (RC) with pelvic lymph node dissection (pLND) represents the gold 
standard for management of non-metastatic muscle invasive bladder cancer (MIBC) and 
refractory non-muscle invasive disease. More interest has been spurred in robot-assisted radical 
cystectomy (RARC) aiming at improving perioperative outcomes, including blood loss, 
transfusion rates, hospital stay and recovery without compromising oncological efficacy 
1,2
. 
Consequently, the past decade has witnessed a paramount shift in the utilization of RARC (from 
<1% in 2004 to 13% in 2010) 
2
. Nevertheless, much of the criticism to RARC has been attributed 
to lack of long term oncologic outcomes and patient selection bias 
3
. There have been concerns 
regarding adherence to key oncologic tenets and induction of local pelvic, peritoneal and port-
site recurrences during minimally invasive approaches to RC 
4
. 
Despite aggressive management, more than half of patients with MIBC will relapse 
(locally or systemically), usually within the first 2 years after surgery with deleterious impact on 
survival 
5,6
. These relapses may be related to the disease aggressiveness or breaching of 
oncologic principles during surgery. Predictors of disease relapse include perioperative 
chemotherapy, extent of pLND, pathological T stage, lymph node status, and positive soft tissue 
surgical margins at cystectomy 
7
.  
In this study we queried the multi-national, prospectively maintained, quality assurance 
database—the International Robotic Cystectomy Consortium (IRCC) to investigate the 
prevalence of early oncologic failure (EOF). EOF was defined as any disease relapse within the 
first 3 months following surgery, among patients who underwent RARC over more than a 
decade, and further to investigate the possible factors contributing to EOF.  
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Methods 
A retrospective review of 2648 patients from 29 institutions included in the IRCC 
database (I-97906) was performed. Six institutions (n=556) that failed to provide updated data 
were excluded from the study. The final cohort comprised 1894 patients from 23 institutions 
across 11 countries treated with RARC since 2003 (Figure 1). Data were reviewed for 
demographics (age, gender, body mass index [BMI], and American Society of Anesthesiologists 
[ASA] score), preoperative characteristics (neoadjuvant chemotherapy, prior abdominal surgery, 
and clinical staging), operative variables (type and technique of diversion, operative time, 
estimated blood loss, and blood transfusion), perioperative outcomes (complications, 
readmissions, hospital and intensive care unit stay), and pathologic outcomes (staging, lymph 
node yield and soft tissue surgical margins). Technique of RARC and urinary diversion differed 
by institution.  
Disease relapses were defined in terms of recurrence type (local, distant, port-site or 
peritoneal carcinomatosis), anatomical site, and timing since cystectomy (EOF—defined as any 
disease relapse within 90 days following RARC; versus later; or no recurrences). All patients had 
at least 3 months of follow up. For all EOF patients, institutions were surveyed for their use of 
pneumoperitoneum pressure, any breach of oncological principles during RARC, technique of 
specimen and lymph node removal, and whether urine spillage occurred during the procedure.  
Descriptive statistics were used to summarize the data. Univariable associations were 
statistically assessed using Pearson Chi-square or Fisher’s Exact test. Univariate and multivariate 
(stepwise variable selection) logistic regression models were fit to evaluate preoperative, 
operative, and postoperative predictors of EOF following RARC. The Kaplan Meier method was 
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used to depict disease-specific and overall survival for patients with EOF versus those who did 
not exhibit EOF. All tests were two-sided, with statistical significance defined as p<0.05. All 
statistical analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary, 
NC). 
Results 
Of the 1894 patients included in the study, 30 patients died because of non-cancer related 
causes and were excluded. A total of 1380 patients had complete data and were included in the 
final analysis (Figure 1). After a mean follow up of 24 months, 305 patients (22%) experienced 
disease relapse, 220 (16%) developed distant, 154 (11%) local recurrence, 17 (1%) peritoneal 
carcinomatosis and 5 (0.4%) port-site recurrences. Seventy-one patients (5%) from 10 
institutions developed EOF, and the incidence of EOF decreased from 10% in 2006 to 6% in 
2015 (Figure 2). Compared with patients who developed later or no recurrences, patients who 
experienced EOF significantly experienced higher estimated blood loss, received blood 
transfusion and adjuvant chemotherapy more frequently, and demonstrated higher complication 
rate. Patients with EOF when compared to patients who developed recurrences > 3months and 
those without any recurrences, they had higher prevalence of pT3, (75% versus 68% and 31%, 
respectively, p<0.001), and positive nodal disease (42% versus 36% and 15%, respectively, 
p<0.0001). They had higher positive soft tissue surgical margins compared to patients who did 
not have any recurrences (13% versus 6%, p<0.001) (Table 1). Eight patients experienced EOF 
despite having organ confined disease (<pT3 and N0).  
Overall, the pelvis was the commonest site for local recurrence (51%). The lung was the 
most common site for distant recurrence (24%) followed by bone metastasis (21%) and 
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extrapelvic lymph node (20%). When compared to those who developed later recurrences, 
patients with EOF experienced more pelvic recurrences (37% versus 22%, p=0.02), extrapelvic 
lymph node metastasis (23% versus 12%, p=0.03), and bone metastasis (24% versus 12%, 
p=0.03) (Table 2).  
We surveyed the 10 institutions that had patients with EOF. Four institutions operated at 
higher pneumoperitoneum pressures ≥14 mmHg, while the remaining operated at ≤12 mmHg. Of 
the patients who developed EOF, 4 patients from 2 institutions had possible disseminated disease 
on preoperative metastatic work up. Breaching of oncologic principles occurred in 6 patients 
(Table 3). 
On multivariate analysis, presence of any complication (Odds ratio [OR] 2.87; 95% 
confidence interval [CI] 1.38-5.96; p=0.004), extravesical disease (OR 3.73, 95% CI 2.00-6.97, 
p<0.001), and nodal involvement (OR 2.14, 95% CI 1.21-3.80, p=0.008) were significant 
predictors of EOF (Table 4). Patients with EOF demonstrated worse DSS (32% and 26%) and 
OS (23% and 13%) at 1 and 3 years when compared to patients who experienced later 
recurrences (DSS 81% and 39%; OS 74% and 25%) and no recurrences (DSS 99% and 96%; OS 
93% and 82%) (log rank p<0.001) (Figures 3 and 4). On Cox proportional hazards analysis, 
patients with pT≥3, nodal involvement, and presence of positive soft tissue surgical margins 
exhibited worse DSS and OS. Patients who received neobladders demonstrated better OS (HR 
0.49, 95% CI 0.31-0.75, p=0.001) (Table 5).  
Discussion 
Despite aggressive management, disease relapse after RC will invariably occur in half of 
the patients which significantly reduces survival. The exact pathogenesis of recurrence following 
9 
 
RC is yet to be determined. Tumor aggressiveness, inhibited host immune response, 
laparoscopy-related factors (gas insufflation and desufflation), or breaching of oncologic surgical 
principles (vigorous surgical manipulation, specimen morcellation, entry into the bladder, and 
retrieval method) have been investigated 
8-10
. The contribution of carbon dioxide (CO2) 
pneumoperitoneum deployed in minimally invasive surgery remains unknown. Prior animal 
studies suggested that CO2 pneumoperitoneum may inhibit peritoneal immune response against 
malignant urothelial cells and may be contributing to recurrences within the pelvis and at port 
sites 
11
. 
We identified and characterized patients who developed EOF after RARC. Five percent 
of our patients experienced EOF. All of these patients but 8 (11%) had advanced disease (≥pT3 
+/- positive nodal disease), and oncologic principles were breached in 6 (8%). For any RC 
performed (open and RARC), tumor stage, nodal involvement, lympho-vascular invasion and 
positive margins are the most powerful predictors of tumor recurrence 
1,12
. Similarly, on 
multivariable analysis, patients with extravesical or nodal disease were at least twice more likely 
to develop EOF. During RC, tumor spillage may occur with extravesical, extensive nodal 
involvement, or due to technical error, which risks seeding the peritoneal cavity with TCC. 
Although its efficacy is unproven, a common practice reported is to irrigate the abdomen with 
sterile water, presumably to induce hypotonic lysis of any remaining TCCs 
13
. The Roswell Park 
Cancer Institute group initiated a novel approach to objectively evaluate the presence of cancer 
cells and their gene-related products in the pelvis and pneumoperitoneum during RARC 
14
. 
Recurrent TCC, presumably from tumor spillage during TURBT or after RC, or from circulating 
tumor cells, has been reported in abdominal wounds, suprapubic tube sites, in the pelvic cavity 
(resection bed), and on the psoas muscle 
15-18
. The use of prophylactic radiation or systemic 
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chemotherapy in the setting of TCC spillage remains unclear with significant potential 
morbidity. This raises questions about the possible role of intraperitoneal chemotherapy similar 
to ovarian, gastric and colorectal malignancies 
19,20
. It is worth mentioning that the incidence of 
EOF decreased with time (from 10% in 2006 to 6% in 2015). If these recurrences are surgery-
related, then this trend might be explained by the evolution of the technique of RARC with time, 
and increased experience and comfort with the robot-assisted platform 
21
. Blood transfusion and 
poor renal function have been also suggested to induce recurrences by affecting the immunity 
and DNA repair 
22
. Although patients who had any recurrence received blood transfusion more 
frequently, it did not reach statistical significance on multivariable analysis. Patients who 
received neobladders exhibited better OS (HR 0.49). Patients who developed postoperative 
complications were approximately 3 times more likely to develop EOF. Complications 
(especially early in the postoperative period) may be a result of inadequate surgical performance 
and therefore may affect cancer control and patient survival 
23
. Patients who receive neobladders 
are generally of better health and less comorbidities. This may explain why the type of diversion 
affected OS and not CSS. 
Time to oncologic failure has been shown to be a significant predictor of overall survival 
6
. Early unexpected relapse was observed in a cohort of patients with favorable pathology (pT2 
N0 Ro or less) in the European Association of Urology Section of Uro-Technology (ESUT) 
cohort 
24
. However, they defined early progression as any disease recurrence within 24 months 
after surgery. Since most recurrences after RC develop within the first 2-3 years after surgery, a 
period of 24 months will make it harder to differentiate recurrences that occur due to advanced 
disease from those that may have occurred due to breech of oncologic surgical principles. In our 
study, patients with EOF demonstrated worse DSS and OS when compared to patients who 
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experienced later recurrences and no recurrences (log rank p<0.0001). Early failures may be a 
result of unrecognized metastatic disease before surgery, or occurs as a result of tumor spillage 
during the procedure. Current imaging techniques lack adequate sensitivity and specificity, 
especially in low-volume metastatic disease. Moreover, it has been shown that in patients with 
presumably organ confined disease; micrometastatic disease was detected using RT-PCR studies 
in up to one third of patients with histologically negative lymph nodes 
25,26
. Similarly, patients 
with colorectal, ovarian and urothelial cancers with local relapse, port site seeding and early 
metastasis after laparoscopic surgery have been previously reported 
21,27
. It remains difficult to 
contemplate whether such recurrences occurred due to the primary tumor or as a result of the 
surgical procedure itself. The use of quality scoring can objectively assess and quantify surgical 
performance and assess the surgical factors that may be contribute to EOF 
23
. 
Interestingly, pneumoperitoneum pressure was not associated with EOF. Prior reports 
suggested that high and/or pulsatile pneumoperitoneum, especially in lengthy procedures, may 
enhance migration tumor cells from the venous plexus of the bladder (whose pedicles are 
squeezed throughout the procedure) and contribute to early tumor recurrence 
8,28,29
. Identifying 
patients who are at higher risk for EOF will provide valuable information for technique 
modification, preventive measures, patient counselling, risk stratification and prognostication. 
Despite the emerging role of RARC as a viable alternative to the open traditional 
approach, criticisms regarding the RARC literature include lack of long term survival data, 
inherent patient selection bias, in addition to longer operative times and associated cost. In our 
cohort, EOF patients experienced more extrapelvic lymph node metastasis when compared to 
later recurrences (23% versus 12%, p=0.03). Nguyen et al suggested that recurrence patterns may 
differ between open and RARC. They reported higher incidence of extrapelvic lymph node 
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metastasis and peritoneal carcinomatosis with RARC 
30
. Less thorough lymph node dissection 
with RARC and possible peritoneal dissemination of malignant urothelial cells with 
pneumoperitoneum have been implicated 
31
. However, the lymph node yield in the same study 
was the same for either approach and the differences reported were not statistically significant. 
Additionally, the approach to cystectomy was not a significant predictor on multivariable 
analysis 
31
. In our cohort, peritoneal carcinomatosis occurred in less than 1% of all patients, and 
represented 4% of all recurrences. This difference may be in part attributed to differences in 
defining carcinomatosis, sample size, follow up and perhaps surgical technique.  
Despite the uniqueness of this study, the retrospective study design and the multi-
institutional and multi-national databases have their recognized limitations. Also, heterogeneity 
in institutional protocols, surgical techniques, and pathological examination may lead to 
variation in reporting outcomes. However, the IRCC represents the largest multinational 
database for RARC that captures and reflects real-world practices.  
Conclusion 
The incidence of EOF following RARC is low and has decreased with time. Disease-
related rather than technical or laparoscopy-related factors play a major role in occurrence of 
EOF after RARC. 
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Table 1. Demographics, clinical characteristics and perioperative outcomes of patients who 
experienced EOF after RARC versus those who did not. 
Preoperative parameters EOF Later Recurrence No Recurrence p-value 
N of patients (%) 71 234 1075 - 
Age at cystectomy, mean (SD) (yr) 64 (13) 68 (10) 67 (10) 0.02 
Gender, Males n (%) 47 (66) 176 (75) 788 (74)  0.31  
Body Mass Index, mean (SD) (kg/m
2
) 26.7 (5.1) 27.2 (5.5) 27.7 (5.2) 0.20 
ASA score, mean (SD) 2 (0.70) 2 (0.65) 2 (0.67) 0.38 
Prior abdominal/pelvic surgery, n (%) 26 (52) 69 (46) 299 (48) 0.76 
Neo-adjuvant chemotherapy, n (%) 16 (25) 45 (20) 207 (21) 0.68 
Perioperative outcomes 
Type of diversion, Ileal conduit, n (%) 55 (86) 188 (87) 810 (81) 0.08 
Technique of diversion, Intracorporeal, n (%) 39 (75) 127 (72) 642 (82) 0.007 
Operative time, median (min) (IQR) 392 (328-474) 373 (316- 454) 374 (311- 451) 0.65 
Estimated blood loss, mean (ml) 541 (690) 498 (417) 383 (411) <0 .001 
Blood Transfusion, n (%) 7 (10) 25 (11) 67 (6) 0.038 
Adjuvant chemotherapy, n (%) 29 (45%) 94 (44%) 72 (8%) < 0.001 
Hospital stay, mean (SD) (d) 12 (10) 12 (9) 12 (12) 0.32 
Intensive Care Unit stay, mean (SD) (d) 1 (3) 1 (3) 1 (2) 0.70 
Postoperative complications, n (%) 
 Any complication 53 (75) 147 (63) 615 (57) 0.007 
 Clavien 3-5 14 (20) 27 (12) 131 (12) 0.159 
 30-d complications 29 (41) 76 (33) 294 (27) 0.001 
  30-90 d complications 7 (10) 17 (7) 60 (6) 
 > 90-d complications 4 (6) 28 (12) 75 (7) 
Follow up, median (months) (IQR) 4 (3-11) 15 (9-27) 19 (8-32) < 0.001 
Time to recurrence, median (months) (IQR) 2 (1-3) 8 (5-17) -  
Pathological outcomes 
Pathologic T stage, ≥pT3, n (%) 51 (75) 148 (68) 317 (31) < 0.001 
Lymph node yield, mean  16 (10) 18 (12) 18 (11) 0.402 
N positive, n (%) 30 (42) 84 (36) 159 (15) < 0.001 
Positive surgical margins, n (%) 9 (13) 31 (13) 65 (6) < 0.001 
EOF, early oncologic failure; SD, standard deviation; Kg/m
2
, Kilogram per square meters; Ml, milliliter 
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Table 2. Sites of disease relapse as a proportion of all relapses (distant+local) 
Local recurrence 
 
 EOF Later 
recurrences 
p-value 
 
Pelvis 26 (37) 52 (22) 0.02 
Vagina 1 (1) 3 (1) 1.00 
Rectum 4 (6) 9 (4) 0.51 
Perineum 4 (6) 8 (3) 0.49 
Urethra 0 6 (3) 0.34 
Penile 2 (3) 0 0.06 
Neobladder/Conduit 2 (3) 2 (1) 0.24 
Kidney 1 (1) 3 (1) 1.00 
Multiple Local  7 (10) 15 (6) 0.48 
Unidentified site 2 (3) 34 (15) NA 
Distant recurrence EOF Later 
recurrences 
p-value 
 
Nodal 16 (23) 27 (12) 0.03 
Lung 11 (15) 41 (18) 0.83 
Liver 10 (14) 15 (6) 0.07 
Bone 17 (24) 29 (12) 0.03 
Brain 3 (4) 2 (1) 0.09 
Abdominal wall 2 (3) 5 (2) 0.67 
Multiple distant 17 (24) 24 (10) 0.006 
Unidentified site 7 (10) 88 (38) NA 
Peritoneal carcinomatosis 6 (8) 11 (5) 0.25 
Port-site recurrence 3 (4) 2 (1) 0.09 
Local and distant recurrence 20 (28) 53 (23) 0.43 
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Table 3. Surveys collected from the lead surgeons of the institutions whose patients experienced 
EOF.  
Survey  n (%) 
Patients with EOF, n 71 
Institutions, n 10 
Suspicious preoperative metastatic work up, n (%) 3 (4)* 
Pneumoperitoneum pressure used (12 or less mmHg), n 
(%)                                                     
13 (18) 
Inadvertent Bladder Entry  1 (1) 
Urine spillage  2 (3) 
Tumor Spillage 2 (3) 
Ureters and urethra not clipped before extirpation  0 
Specimen (bladder/Lymph nodes) not retrieved in a bag 1 (1) 
*
 Two patients had possible nodal disease and 1 had possible lung 
metastasis on preoperative metastatic work up 
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Table 4. Univariate and multivariable regression modeling predictors for EOF (stepwise variable 
selection) 
 
Variables [Reference] 
Univariate Multivariate 
OR  95% CI p-value OR  95% CI p-value 
Preoperative parameters    
Age at cystectomy 0.97 (0.95, 0.99) 0.01 - - - 
Gender [Female] 0.69 (0.43, 1.14) 0.14 - - - 
Body Mass Index 0.97 (0.92, 1.02) 0.18 - - - 
ASA score 0.77 (0.52, 1.13) 0.18 - - - 
Neo-adjuvant chemotherapy  1.28 (0.72, 2.29) 0.41 - - - 
Operative    
Type of diversion [Ileal Conduit] 0.73 (0.36, 1.50) 0.39 - - - 
Technique of diversion [Extracorporeal] 0.73 (0.38, 1.40) 0.35 - - - 
Operative time  1.08 (0.94, 1.23) 0.28 - - - 
Estimated blood loss  1.05 (1.00, 1.09) 0.03 - - - 
Blood Transfusion  1.45 (0.64, 3.25) 0.37 - - - 
Adjuvant therapy  4.45 (2.66, 7.47) < 0.001 - - - 
Intensive care unit stay 1.02 (0.90, 1.16) 0.76 - - - 
Hospital stay 1.00 (0.98, 1.02) 0.91 - - - 
Any complication  2.11 (1.22, 3.65) 0.006 2.87 (1.38, 5.96) 0.004 
Clavien ≥ 3 complications  1.79 (0.97, 3.29) 0.06 - - - 
Pneumoperitoneum pressure [12mmHg] 1.47 (0.79, 2.76) 0.22 - - - 
Breaching of oncologic principles [No] 1.52 (0.86, 2.71) 0.15 -  - - 
Pathologic    
≥pT3 stage  4.95 (2.82, 8.67) < 0.001 3.73 (2.00, 6.97) < 0.001 
pN1 3.21 (1.96, 5.25) < 0.001 2.14 (1.21, 3.80) 0.008 
Lymph Node Yield 0.99 (0.96, 1.01) 0.22 - - - 
Positive surgical margins [No] 1.83 (0.88, 3.80) 0.10 - - - 
RARC, robotic-assisted laparoscopic radical cystectomy; SD, standard deviation; NA, odds ratio calculation impossible 
due to zero cell count(s) 
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Table 5. Cox proportional hazards modelling predictors of DSS and OS 
Overall survival 
Parameter HR 95% CI p-value 
≥pT3 3.302 2.56-4.25 <.0001 
pN1 1.796 1.40-2.30 <.0001 
Positive margins 1.578 1.13-2.21 0.0076 
Neobladders 0.484 0.31-0.75 0.0012 
Disease-specific survival 
Parameter HR 95% CI p-value 
≥pT3 4.94 3.30-7.40 <0.0001 
pN1 2.26 1.58-3.22 <0.0001 
Positive margins 1.64 1.03-2.63 0.04 
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Figure 1. Study cohort 
 
Figure 2. EOF cases as they occurred with time (Linear Regression Test p = 0.15) 
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Figure 3. Kaplan Meier curves for OS (log rank p <0.001) 
 
EOF Patients 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 71 30 12 8 6 6 
Patient Deaths 36 14 3 2 0 0 
Survival % 46.6 22.8 16.7 12.5 12.5 12.5 
 
Later Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 234 211 152 100 68 49 
Patient Deaths 14 42  40 24 14 10 
Survival % 93.9 74.4 54.1 40.6 31.8 24.8 
 
No Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 1075 894 698 552 434 312 
Patient Deaths 28 32 23 15 10 12 
Survival %  97.2 93.4 90.0 87.3 85.0 81.5 
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Figure 4. Kaplan Meier curves for DSS (log rank p <0.001) 
 
EOF Patients 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 71 30 12 8 6 6 
Patient Deaths 31 9 2 0 0 0 
Survival % 51.4 32.2 25.8 25.8 25.8 25.8 
 
Later Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 234 211 152 100 68 49 
Patient Deaths 9 31 32 16 9 5 
Survival % 96.0 80.8 62.6 51.8 44.3 39.4 
 
No Recurrence 
Months 0-6 6-12 12-18 18-24 24-30 30-36 
Patients At Risk 1075 894 698 552 434 312 
Patient Deaths 4 7 4 3 20 3 
Survival % 99.6 98.7 98.1 97.5 96.9 95.9 
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